Study M1128
Study name | Zada W 2022 |
Title | Fatty acid amide hydrolase inhibition and N-arachidonoylethanolamine modulation by isoflavonoids: a novel target for upcoming antidepressants |
Overall design | The aim of this study was to explore the therapeutic potential of three specific isoflavonoid compounds (7-hydroxyflavone, biochanin-A, and genistein). Male and female CD1 mice were divided into the following 6 groups (n = 8 in each group): (1) control group, (2) fluoxetine group (fluoxetine treatment at the dose of 10 mg/kg), (3) arachidonyl serotonin group (arachidonyl serotonin treatment at the dose of 5 mg/kg), (4) 7-hydroxyflavone group (7-hydroxyflavone treatment at the dose of 20 mg/kg), (5) biochanin-A group (biochanin-A treatment at the dose of 30 mg/kg), and (6) genistein group (genistein treatment at the dose of 20 mg/kg). Mice underwent 14 consecutive days of intra-peritoneal drug administration, followed by forced swim test. All treatments significantly decreased immobility time in both male and female mice in the forced swim test. LC-MS was used to determine the anandamide concentrations in the prefrontal cortex (n = 4-8 per group per sex). |
Study Type | Type3; |
Data available | Unavailable |
Organism | Mouse; CD1 mouse; |
Categories of depression | Healthy individuals; Healthy individuals; Healthy individuals; |
Criteria for depression | Forced swimming test |
Sample size | 60 |
Tissue | Central; Brain; Prefrontal cortex; |
Platform | MS-based; LC-MS: Eksigent Ekspert micro liquid chromatographer 200 with AB SciexQtrap5500 mass spectrometer; |
PMID | |
DOI | |
Citation | Zada W, VanRyzin JW, Perez-Pouchoulen M, et al. Fatty acid amide hydrolase inhibition and N-arachidonoylethanolamine modulation by isoflavonoids: a novel target for upcoming antidepressants. Pharmacol Res Perspect. 2022 Oct;10(5):e00999. |
Metabolite |
